Is RELIANCINS undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6
Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of RELIANCINS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: RELIANCINS (BDT58.1) is trading above our estimate of fair value (BDT47.14)
Significantly Below Fair Value: RELIANCINS is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for RELIANCINS?
Key metric: As RELIANCINS is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
The above table shows the Price to Earnings ratio for RELIANCINS. This is calculated by dividing RELIANCINS's market cap by their current
earnings.
What is RELIANCINS's PE Ratio?
PE Ratio
7.4x
Earnings
৳823.92m
Market Cap
৳6.11b
RELIANCINS key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue
1x
Enterprise Value/EBITDA
1.8x
PEG Ratio
n/a
Price to Earnings Ratio vs Peers
How does RELIANCINS's PE Ratio compare to its peers?
The above table shows the PE ratio for RELIANCINS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Price-To-Earnings vs Industry: RELIANCINS is good value based on its Price-To-Earnings Ratio (7.4x) compared to the BD Insurance industry average (17.7x).
Price to Earnings Ratio vs Fair Ratio
What is RELIANCINS's PE Ratio
compared to its
Fair PE Ratio?
This is the expected PE Ratio taking into
account the company's forecast earnings growth, profit margins
and other risk factors.
RELIANCINS PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio
7.4x
Fair PE Ratio
n/a
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate RELIANCINS's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.